» Articles » PMID: 28056439

FeO Nanoparticles on Graphene Oxide Sheets for Isolation and Ultrasensitive Amperometric Detection of Cancer Biomarker Proteins

Overview
Date 2017 Jan 6
PMID 28056439
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Ultrasensitive mediator-free electrochemical detection for biomarker proteins was achieved at low cost using a novel composite of FeO nanoparticles loaded onto graphene oxide (GO) nano-sheets (FeO@GO). This paramagnetic FeO@GO composite (1µm size range) was decorated with antibodies against prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA), and then used to first capture these biomarkers and then deliver them to an 8-sensor detection chamber of a microfluidic immunoarray. Screen-printed carbon sensors coated with electrochemically reduced graphene oxide (ERGO) and a second set of antibodies selectively capture the biomarker-laden FeO@GO particles, which subsequently catalyze hydrogen peroxide reduction to detect PSA and PSMA. Accuracy was confirmed by good correlation between patient serum assays and enzyme-linked immuno-sorbent assays (ELISA). Excellent detection limits (LOD) of 15 fg/mL for PSA and 4.8 fg/mL for PSMA were achieved in serum. The LOD for PSA was 1000-fold better than the only previous report of PSA detection using FeO. Dynamic ranges were easily tunable for concentration ranges encountered in serum samples by adjusting the FeO@GO Concentration. Reagent cost was only $0.85 for a single 2-protein assay.

Citing Articles

Electrochemical Biosensors for Cancer Diagnosis: Multitarget Analysis to Present Molecular Characteristics of Tumor Heterogeneity.

Cao Y, Xia J, Li L, Zeng Y, Zhao J, Li G JACS Au. 2024; 4(12):4655-4672.

PMID: 39735934 PMC: 11672140. DOI: 10.1021/jacsau.4c00989.


An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success.

Kumbhar P, Kumar P, Lasure A, Velayutham R, Mandal D Discov Nano. 2023; 18(1):156.

PMID: 38112935 PMC: 10730792. DOI: 10.1186/s11671-023-03913-6.


Multiplexed electrochemical assays for clinical applications.

Sharafeldin M, Rusling J Curr Opin Electrochem. 2023; 39.

PMID: 37006828 PMC: 10062004. DOI: 10.1016/j.coelec.2023.101256.


Molecular Diagnosis and Cancer Prognosis-A Concise Review.

Thenrajan T, Alwarappan S, Wilson J Diagnostics (Basel). 2023; 13(4).

PMID: 36832253 PMC: 9955694. DOI: 10.3390/diagnostics13040766.


Sonophotocatalytic degradation of malachite green in aqueous solution using six competitive metal oxides as a benchmark.

El-Sawy A, Salem M, Salem I, Hydara M, Zaki A Photochem Photobiol Sci. 2022; 22(3):579-594.

PMID: 36434430 DOI: 10.1007/s43630-022-00336-7.


References
1.
Zhang Y, Guo Y, Xianyu Y, Chen W, Zhao Y, Jiang X . Nanomaterials for ultrasensitive protein detection. Adv Mater. 2013; 25(28):3802-19. DOI: 10.1002/adma.201301334. View

2.
Xiao Z, Adam B, Cazares L, Clements M, Davis J, Schellhammer P . Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001; 61(16):6029-33. View

3.
Lequin R . Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005; 51(12):2415-8. DOI: 10.1373/clinchem.2005.051532. View

4.
Loh K, Bao Q, Eda G, Chhowalla M . Graphene oxide as a chemically tunable platform for optical applications. Nat Chem. 2010; 2(12):1015-24. DOI: 10.1038/nchem.907. View

5.
Malhotra R, Patel V, Chikkaveeraiah B, Munge B, Cheong S, Zain R . Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array. Anal Chem. 2012; 84(14):6249-55. PMC: 3418660. DOI: 10.1021/ac301392g. View